LLY

1,058.87

+1.65%↑

JNJ

203.92

+0.27%↑

ABBV

236.16

+2.85%↑

UNH

319.35

+2.41%↑

AZN

91.01

+2.64%↑

LLY

1,058.87

+1.65%↑

JNJ

203.92

+0.27%↑

ABBV

236.16

+2.85%↑

UNH

319.35

+2.41%↑

AZN

91.01

+2.64%↑

LLY

1,058.87

+1.65%↑

JNJ

203.92

+0.27%↑

ABBV

236.16

+2.85%↑

UNH

319.35

+2.41%↑

AZN

91.01

+2.64%↑

LLY

1,058.87

+1.65%↑

JNJ

203.92

+0.27%↑

ABBV

236.16

+2.85%↑

UNH

319.35

+2.41%↑

AZN

91.01

+2.64%↑

LLY

1,058.87

+1.65%↑

JNJ

203.92

+0.27%↑

ABBV

236.16

+2.85%↑

UNH

319.35

+2.41%↑

AZN

91.01

+2.64%↑

Home・Aandelen Lijst・Ventyx Biosciences Inc

Ventyx Biosciences Inc

Gesloten

9.4 -2.08

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

8.88

Max

9.58

Belangrijke statistieken
By Trading Economics
Inkomsten	4.2M -23M
Winstmarge	-2,027.003
Werknemers	83
EBITDA	6.6M -23M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+42.25% upside

Marktinformatie
By TradingEconomics
Marktkapitalisatie	91M 678M
Vorige openingsprijs	11.48
Vorige sluitingsprijs	9.4

Ventyx Biosciences Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

21 nov 2025, 22:42 UTC

Marktinformatie

Fitch Raises Cyprus's Outlook to Positive From Stable -- Market Talk

21 nov 2025, 21:50 UTC

Marktinformatie

Winsten

Tech, Media & Telecom Roundup: Market Talk

21 nov 2025, 21:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

21 nov 2025, 21:47 UTC

Marktinformatie

Mexico's 3Q GDP Prompts Growth Downgrades -- Market Talk

21 nov 2025, 21:43 UTC

Marktinformatie

U.S. Crude Production Defies Low Prices, Rig Count -- Market Talk

21 nov 2025, 20:18 UTC

Marktinformatie

Oil Futures Fall on U.S. Push for Russia-Ukraine Peace -- Market Talk

21 nov 2025, 20:14 UTC

Marktinformatie

U.S. Natural Gas Gains As Traders Focus on Weather -- Market Talk

21 nov 2025, 19:48 UTC

Marktinformatie

Precious Metals Fall for the Week -- Market Talk

21 nov 2025, 19:44 UTC

Winsten

Deere Earnings, Inflation Data, Black Friday: What to Watch in the Next Week -- WSJ

21 nov 2025, 19:37 UTC

Marktinformatie

Dollar Stalls as Stocks and Bonds Rise -- Market Talk

21 nov 2025, 19:27 UTC

Marktinformatie

Winsten

Global Equities Roundup: Market Talk

21 nov 2025, 19:27 UTC

Marktinformatie

Winsten

Intuit Seen With Underappreciated Credit Karma Momentum -- Market Talk

21 nov 2025, 19:20 UTC

Marktinformatie

European Natural Gas Premium Versus U.S. Shrinks -- Market Talk

21 nov 2025, 18:44 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Palo Alto-Chronosphere Synergies Questioned Despite M&A Record -- Market Talk

21 nov 2025, 18:37 UTC

Marktinformatie

U.S. Oil Rig Count Rises By 2 to 419 -- Market Talk

21 nov 2025, 18:34 UTC

Marktinformatie

Winsten

Intuit Seen Outperforming on Conservative Guidance -- Market Talk

21 nov 2025, 18:28 UTC

Winsten

Veeva Systems Earnings Beat Expectations. Why the Stock Is On Pace for Its Largest Drop Since 2023. -- Barrons.com

21 nov 2025, 18:03 UTC

Marktinformatie

Mexico's Inflation Seen Up Slightly in Early November -- Market Talk

21 nov 2025, 17:24 UTC

Marktinformatie

Global Equities Roundup: Market Talk

21 nov 2025, 17:24 UTC

Marktinformatie

Intuit Seen on Path to Increase Growth -- Market Talk

21 nov 2025, 17:20 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

21 nov 2025, 17:05 UTC

Marktinformatie

Lowe's Getting Boost From Busy Small to Medium Pro Customer -- Market Talk

21 nov 2025, 16:56 UTC

Marktinformatie

Gold Recovers as Investors Boost Rate-Cut Bets -- Market Talk

21 nov 2025, 16:47 UTC

Marktinformatie

European Gas-Price Forecast to Decline Further on Expanding LNG Supply -- Market Talk

21 nov 2025, 16:35 UTC

Acquisities, Fusies, Overnames

What Stocks Al Gore's Investment Firm Bought and Sold This Quarter -- Barrons.com

21 nov 2025, 16:09 UTC

Winsten

Veeva Systems Earnings Beat Expectations. Why the Stock Is On Pace for Its Largest Drop Since 2023. -- Barrons.com

21 nov 2025, 15:59 UTC

Marktinformatie

Canadian Consumers Tapping the Brakes, Still See Resilient -- Market Talk

21 nov 2025, 15:59 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

21 nov 2025, 15:23 UTC

Marktinformatie

Bank of Canada Not Expected to Be Swayed by Canadian Retail Trade Data -- Market Talk

21 nov 2025, 15:17 UTC

Marktinformatie

Canadian Consumer Spending Softening, But Could Be Worse -- Market Talk

Peer Vergelijking

Prijswijziging

Ventyx Biosciences Inc Prognose

Koersdoel

By TipRanks

42.25% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 13.67 USD 42.25%

Hoogste 21 USD

Laagste 2 USD

Gebaseerd op 7 Wall Street-analisten die 12-maands prijsdoelen bieden voor Ventyx Biosciences Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

7 ratings

Buy

Hold

Sell

Gebaseerd op 7 analisten die aandelenratings hebben gegeven aan Ventyx Biosciences Inc - Dist in de afgelopen 3 maanden.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Ventyx Biosciences Inc

Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in San Diego, California.